Literature DB >> 9017779

Warfarin-fluoxetine and diazepam-fluoxetine interaction.

L A Dent1, M W Orrock.   

Abstract

Fluoxetine and its metabolite norfluoxetine are eliminated by oxidative metabolism via the CYP450 system and may inhibit the oxidative metabolism of other drugs to various degrees. A fluoxetine-warfarin interaction has been postulated, but is not well documented in the literature. The elimination of diazepam may also be inhibited by fluoxetine. An elderly man was prescribed these three drugs in combination and experienced such an interaction. He developed an elevated international normalized ratio (INR) and died from a cerebral hemorrhage. He also manifested drug delirium secondary to inhibited diazepam metabolism. In elderly patients receiving fluoxetine, lorazepam or oxazepam would be safer alternatives to diazepam since they are conjugated in the liver. Patients stabilized on warfarin should be monitored closely for changes in INR if fluoxetine is added or deleted.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9017779

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

Review 3.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.

Authors:  Martina Teichert; Loes E Visser; Andrė G Uitterlinden; Albert Hofman; Peter J Buhre; Sabine Straus; Peter A G M De Smet; Bruno H Stricker
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 5.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

Authors:  Adrián LLerena; Pedro Dorado; Roland Berecz; Antonio P González; Eva M Peñas-LLedó
Journal:  Eur J Clin Pharmacol       Date:  2004-01-16       Impact factor: 2.953

7.  Warfarin and Antidepressants: Happiness without Hemorrhaging.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2009-07

8.  SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010-2015.

Authors:  Safoura Sheikh Rezaei; Martina Mittlböck; Bertholdt Reichardt; Michael Wolzt
Journal:  Int J Geriatr Psychiatry       Date:  2019-04-24       Impact factor: 3.485

9.  Bupropion-warfarin combination: a serious complication.

Authors:  Amar D Bavle; Akshay S Phatak
Journal:  Indian J Psychol Med       Date:  2013-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.